BTMD — biote Corp.

BTMD Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $48.0 million, down 6.7% year-over-year.
• Procedure Revenue: Declined 10.4%, attributed to slower new clinic additions and lower procedure volumes.
• Dietary Supplements Revenue: Grew 8.4% to $11.2 million, driven by e-commerce growth.
• Gross Profit Margin: Increased to 71.8%, up 150 basis points due to cost savings from vertical integration.
• Net Income: $9.2 million, down from $12.7 million; diluted EPS was $0.22 compared to $0.33.
• Adjusted EBITDA: Decreased 20.5% to $12.9 million, with an adjusted EBITDA margin of 26.9%.
• Cash Flow from Operations: Increased to $27.6 million; cash and cash equivalents rose to $28.0 million.

2. Strategic Updates and Business Highlights

• Strategic Priorities: Focus on accelerating growth from new providers, maximizing value from top-tier clinics, and improving financial performance through accountability.
• Sales Team Transformation: Approximately 50% of the commercial team has been restructured; new hires are being onboarded to enhance sales effectiveness.
• Marketing Event: The annual "Sun, Sea and Biote" event in Cancun attracted over 800 attendees, reinforcing Biote's leadership in hormone optimization.
• Operational Improvements: Enhanced internal processes and systems are expected to drive operational excellence and long-term value creation.

3. Forward Guidance and Outlook

• Fiscal 2025 Revenue Guidance: Reiterated at above $190 million.
• Adjusted EBITDA Guidance: Expected to exceed $50 million.
• Dietary Supplements Growth: Anticipated mid-teens revenue growth for the fiscal year.

4. Bad News, Challenges, or Points of Concern

• Procedure Revenue Decline: The ongoing transformation of the sales team has negatively impacted procedure revenue in the short term.
• Attrition Rates: Elevated attrition rates remain a concern, with no significant improvement noted in Q3.
• Competitive Pressures: Increased competition in the market is affecting customer retention and volume.
• Sales Force Ramp-Up: New hires typically require a 3- to 6-month ramp-up period before becoming fully productive.

5. Notable Q&A Insights

• Sales Hiring Pace: Management reported progress in hiring, with approximately 80 sales representatives onboarded, aiming for full coverage by year-end.
• Impact of Marketing Event: Positive feedback from practitioners at the marketing event suggests potential for improved retention and growth, although trends post-event are still being monitored.
• Donovitz Transactions: The company achieved cash flow savings of approximately $18.6 million through amended agreements with Marci and Gary Donovitz, enhancing financial flexibility.
• Procedure Volume Trends: Management acknowledged challenges in procedure volumes, attributing them to the transition to a new clinical decision support system (CDSS) and the need for improved sales coverage.

This summary encapsulates the key financial metrics, strategic initiatives, outlook, challenges, and insights from the Q3 2025 earnings call for Biote (BTMD).